It is estimated that 350 million people worldwide use biologics on a regular basis to treat their medical conditions. These therapies are incredibly innovative and have expanded the arsenal of effective treatment options for cancer, rheumatoid arthritis, and other serious illnesses. However, the high costs of these therapies, although understandable, can create access issues for patients. That is why biosimilars are so important.
The February issue of The Oncology Nurse-APN/PA (TON) is filled with important news and insights for today’s oncology nurse.
St. Luke’s Cancer Institute, Boise, ID, is celebrating its 50th anniversary this year. Formerly known as Mountain States Tumor Institute, St. Luke’s employs medical and radiation oncology specialists, as well as fellowship-trained cancer surgeons in areas such as thoracic, hepatobiliary, gynecologic, and urologic oncology. The facility also offers autologous and allogeneic bone marrow and stem-cell transplantation and is a National Marrow Donor Program Apheresis Center. In addition, St. Luke’s is home to Idaho’s only pediatric cancer program and federally sponsored hemophilia center.
San Francisco, CA—An increasing number of biosimilars have been approved in the United States, but many clinicians are still poorly informed about what constitutes a biosimilar, and what is involved in their unique pathway to approval, said Andrew D. Zelenetz, MD, PhD, Medical Oncologist, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York City. He discussed this topic at the NCCN 2019 Hematologic Malignancies meeting.
San Francisco, CA—There is no shortage of research on psychosocial issues in patients with cancer, but implementation of this evidence in clinical practice has a long way to go, according to data presented at the 2019 Supportive Care in Oncology Symposium.
Orlando, FL—Today’s patient with cancer is concerned with more than just cell counts. These patients want to discuss topics such as parenting, financial toxicity, and sex and intimacy, according to Laura Holmes Haddad, author of This Is Cancer, and a cancer survivor.
To sign up for our newsletter or print publications, please enter your contact information below.
